HEALEY ALS Platform Trial

Weekly Q&A – June 2, 2022

















Healey Center

Sean M. Healey & AMG Center for ALS at Mass General









































Guest Speaker

Daniel Hevert, BS
Lead Clinical Research Coordinator
Mass General Hospital



The HEALEY ALS Platform Trial is a Perpetual Adaptive Trial



Enrollment Updates (as of June 2, 2022)

• 68 individuals have signed informed consent

44 individuals have been randomized within Regimen E




This breakthrough trial would not be possible without your participation

Your **partnership** in research is what keeps us filled with passion, dedication, and the commitment to uncover new promising treatments for ALS

Every research participant, whether on the active drug or placebo, plays a critical role in making the hope of finding a cure for ALS a reality

36 Sites Currently Activated for Regimen E



(as of 6/2/22)

Sites in blue participated in previous regimens. Sites in green (underlined to the side) are new additions to the Platform Trial!

- Lehigh Valley Health Network
- 🗹 🏻 Mass General Hospital
- University of Kansas
- University of Maryland
- California Pacific Medical Center
- Morthwestern University
- Virginia Commonwealth University
- University of Nebraska
- Washington University
- Wake Forest University
- Hospital for Special Care
- Saint Alphonsus Regional
- University of Massachusetts
- ☑ Duke University
- Barrow Neurological Institute
- Georgetown University
- Texas Neurology
- Beth Israel Deaconess Medical Center
- SUNY Upstate
- Spectrum Health
- Henry Ford Hospital
- Essentia Health
- University of Southern California
- University of South Florida
- University of Colorado
- Providence Brain and Spine
- University of Minnesota
- University of Iowa
- Swedish Medical Center
- Ohio State University
- University of Cincinnati
- Thomas Jefferson University

- UC San Francisco
- 🗹 Mayo Rochester
- University of Washington

Checking Site Status Online

List of Participating Sites

Sites marked "Recruiting" are currently enrolling participants in regimen E.

Sites marked "Active, Not recruiting" are active in the platform (for example, they are following participants in regimens A-D) but are not enrolling new participants at this time. Most active sites are expected to start enrolling in regimen E soon.

Site	State	Enrollment Status	Contact Information
Lehigh Valley Health Network	PA	Recruiting	Andrew Orzel (610-402-9543)
Penn State Hershey	PA	Active, Not recruiting	<u>Heidi Runk</u>



https://bit.ly/3g2NZr5

Patient Navigation Central resource for people living with ALS



Catherine Small



Allison Bulat

Phone: 833-425-8257 (HALT ALS)

E-mail:healeyalsplatform@mgh.harvard.edu

Weekly webinar registration:



https://bit.ly/3r6Nd2L

ALS Link sign-up:



https://bit.ly/3o2Ds3m

Upcoming Guest Speakers:

June 9th- Honora Dalamagas and Natalie Cartwright (Hospital for Special Care, CT)
June 16th- Bruce Rosenblum (EAP Patient Advisory Committee Member)

June 23rd- Jackie Whitesell, MD (Investigator at Saint Alphonsus Medical Center, Idaho)



The ALS Association/Northeast ALS Consortium Educational Webinar

Healey ALS Platform Trial Regimen E: A Participant's Guide

Friday, June 17, 2022 5:00 - 6:00 PM EDT

The purpose of this webinar is to provide an overview of how SLS-005 (trehalose) may help to slow ALS and illustrate what potential participants can expect when enrolling in Regimen E of the Healey ALS Platform Trial. The presenters will review some of the unique aspects of the regimen related to the intravenous administration.

Register Below:



https://bit.ly/3aeT5kc

Recording will later be available under "educational webinars" on neals.org